| Source: |
| Type: Proapototic |
| cyclin-dependent kinase inhibitor p21 (also known as p21 WAF1/Cip1) promotes cell cycle arrest in response to many stimuli. P21 is a cyclin-dependent kinase inhibitor that plays a crucial role in regulating the cell cycle. It is encoded by the CDKN1A gene and is a key player in the cellular response to stress, including DNA damage. P21 is often considered a tumor suppressor because its expression is upregulated in response to p53 activation, a well-known tumor suppressor protein. When DNA damage occurs, p53 can activate the transcription of the CDKN1A gene, leading to increased levels of P21, which helps prevent the proliferation of damaged cells. In many cancers, the p53 pathway is disrupted, leading to decreased levels of P21. p21 is a apoptotic marker protein. Cell cycle arrest gene p21 |
| 1655- | FA, | Ferulic acid inhibiting colon cancer cells at different Duke’s stages |
| - | in-vitro, | Colon, | SW480 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Colon, | HCT116 |
| 2495- | Fenb, | Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells |
| - | in-vitro, | Melanoma, | A375 |
| 2852- | FIS, | A comprehensive view on the fisetin impact on colorectal cancer in animal models: Focusing on cellular and molecular mechanisms |
| - | Review, | CRC, | NA |
| 2859- | FIS, | The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Pathways |
| - | in-vitro, | Liver, | HepG2 | - | NA, | Colon, | Caco-2 |
| 2845- | FIS, | Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy |
| - | Review, | Var, | NA |
| 2825- | FIS, | Exploring the molecular targets of dietary flavonoid fisetin in cancer |
| - | Review, | Var, | NA |
| 2828- | FIS, | Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review |
| - | Review, | Var, | NA |
| 2839- | FIS, | Dietary flavonoid fisetin for cancer prevention and treatment |
| - | Review, | Var, | NA |
| 2832- | FIS, | Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies |
| - | Review, | Var, | NA |
| 1086- | GA, | Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation |
| - | in-vitro, | AML, | K562 |
| 1065- | GA, | Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression |
| - | vitro+vivo, | Pca, | NA |
| 5152- | GamB, | Gambogic Acid as a Candidate for Cancer Therapy: A Review |
| - | Review, | Var, | NA |
| 804- | GAR, | Garcinol inhibits the proliferation of endometrial cancer cells by inducing cell cycle arrest |
| - | in-vitro, | EC, | HEC1B | - | in-vitro, | EC, | ISH |
| 803- | GAR, | Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 1504- | GEN, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | NA, | NA |
| 1638- | HCAs, | Anticancer potential of hydroxycinnamic acids: mechanisms, bioavailability, and therapeutic applications |
| - | Review, | Nor, | NA |
| 2865- | HNK, | Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma |
| - | in-vitro, | MB, | DAOY | - | vitro+vivo, | NA, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2894- | HNK, | Pharmacological features, health benefits and clinical implications of honokiol |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2898- | HNK, | Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism |
| - | in-vitro, | GC, | AGS | - | in-vitro, | GC, | NCI-N87 | - | in-vitro, | BC, | MGC803 | - | in-vitro, | GC, | SGC-7901 |
| 4639- | HT, | Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 1293- | Ins, | Inositol Hexaphosphate Inhibits Growth and Induces G1 Arrest and Apoptotic Death of Androgen-Dependent Human Prostate Carcinoma LNCaP Cells |
| - | vitro+vivo, | Pca, | LNCaP |
| 1923- | JG, | Mechanism of Juglone-Induced Cell Cycle Arrest and Apoptosis in Ishikawa Human Endometrial Cancer Cells |
| - | in-vitro, | Endo, | NA |
| 2906- | LT, | Luteolin, a flavonoid with potentials for cancer prevention and therapy |
| - | Review, | Var, | NA |
| 2914- | LT, | Therapeutic Potential of Luteolin on Cancer |
| - | Review, | Var, | NA |
| 2915- | LT, | Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | CRC, | SNU-407 | - | in-vitro, | Nor, | FHC |
| 3275- | Lyco, | Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer |
| - | Review, | Var, | NA |
| 3276- | Lyco, | Lycopene modulates cellular proliferation, glycolysis and hepatic ultrastructure during hepatocellular carcinoma |
| - | in-vivo, | HCC, | NA |
| 3277- | Lyco, | Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent |
| - | Review, | Var, | NA |
| 1708- | Lyco, | The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies |
| - | Review, | Var, | NA |
| 4786- | Lyco, | Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | SkBr3 |
| 4791- | Lyco, | Investigating into anti-cancer potential of lycopene: Molecular targets |
| - | Review, | Var, | NA |
| 4792- | Lyco, | A Comprehensive Review on the Molecular Mechanism of Lycopene in Cancer Therapy |
| - | Review, | Var, | NA |
| 4518- | MAG, | Cisplatin, | Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells |
| - | in-vitro, | GC, | MKN45 |
| 4514- | MAG, | Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential |
| - | Review, | Var, | NA |
| 4536- | MAG, | Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis |
| - | in-vitro, | Liver, | HepG2 | - | in-vivo, | CRC, | COLO205 |
| 4537- | MAG, | Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action |
| - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | A431 |
| 5252- | MAG, | Insights on the Multifunctional Activities of Magnolol |
| - | Review, | Var, | NA |
| 1782- | MEL, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 2255- | MF, | Pulsed Electromagnetic Fields Induce Skeletal Muscle Cell Repair by Sustaining the Expression of Proteins Involved in the Response to Cellular Damage and Oxidative Stress |
| - | in-vitro, | Nor, | SkMC |
| 487- | MF, | Extremely Low-Frequency Electromagnetic Fields Cause G1 Phase Arrest through the Activation of the ATM-Chk2-p21 Pathway |
| - | in-vitro, | NMSC, | HaCaT |
| 198- | MFrot, | MF, | Biological effects of rotating magnetic field: A review from 1969 to 2021 |
| - | Review, | Var, | NA |
| 1311- | NarG, | Rad, | Naringenin sensitizes lung cancer NCI-H23 cells to radiation by downregulation of akt expression and metastasis while promoting apoptosis |
| - | in-vitro, | Lung, | H23 |
| 1797- | NarG, | Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1015- | NarG, | Naringin induces endoplasmic reticulum stress-mediated apoptosis, inhibits β-catenin pathway and arrests cell cycle in cervical cancer cells |
| - | in-vitro, | Cerv, | SiHa | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | C33A |
| 4630- | OLE, | Targeting resistant breast cancer stem cells in a three-dimensional culture model with oleuropein encapsulated in methacrylated alginate microparticles |
| - | in-vitro, | BC, | NA |
| 4643- | OLE, | HT, | Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine |
| - | Review, | Var, | NA |
| 2069- | PB, | Toxic and metabolic effect of sodium butyrate on SAS tongue cancer cells: role of cell cycle deregulation and redox changes |
| - | in-vitro, | Tong, | NA |
| 2026- | PB, | Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study |
| - | Trial, | GBM, | NA |
| 2028- | PB, | Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:234 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid